Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Food on Tolerability of Abemaciclib in Previously Treated HR-positive, HER2-negative Metastatic Breast Cancer
2018-001853-28Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abemaciclib in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Incidence of severe diarrhea (≥ Grade 3), Incidence of prolonged Grade 2 diarrhea and 1 more. Started Aug 2018; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001853-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001853-28.